Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Previously Presented) A composition which comprises an admixture of two compounds, wherein: (a) one compound is monoclonal antibody PA14 (produced by hybridoma PA14 having ATCC Accession No. HB-12610) or a portion thereof which binds to a CCR5 receptor; and (b) one compound is T-20 having the amino-acid sequence set forth in SEQ ID NO:1; wherein the relative mass ratio of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell.

2. (Previously Presented) A composition which comprises an admixture of three compounds, wherein: (a) one compound is monoclonal antibody PA14 (produced by hybridoma PA14 having ATCC Accession No. HB-12610) or a portion thereof which binds to a CCR5 receptor; (b) one compound is a CD4-IgG2 chimeric heterotetramer comprising two heavy chains and two light chains, wherein the heavy chains are encoded by expression vector CD4-IgG2HC-pRcCMV having ATCC Accession No. 75193 and the light chains are encoded by expression vector CD4-kLC-pRcCMV having ATCC Accession No. 75194; and (c) one compound is T-20 having the amino-acid sequence set forth in SEQ ID NO:1; wherein the relative mass ratio of any two of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell.

3-45. (Canceled)

46. (Previously Presented) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with (1) an amount of monoclonal antibody PA14 (produced by hybridoma PA14 having ATCC Accession No. HB-12610) or a portion thereof which binds to a CCR5 receptor, and (2) an amount of T-20 having the amino-acid sequence set forth in SEQ ID NO:1, so as to thereby inhibit HIV-1 infection of the CD4+ cell.

47. (Currently Amended) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with (1) an amount of monoclonal antibody PA14 (produced by hybridoma PA14 having ATCC Accession No. HB-12610) or a portion thereof which binds to a CCR5 receptor, (2) an amount of a CD4-IgG2 chimeric heterotetramer comprising two heavy chains and two light chains, wherein the heavy chains are encoded by expression vector CD4-IgG2HC-pRcCMV having ATCC Accession No. 75193 and the light chains are encoded by expression vector CD4-kLC-pRcCMV having ATCC Accession No. 75194, and (3) an amount of T-20 having the amino-acid sequence set forth in SEQ ID NO:1, so as to thereby inhibit HIV-1 infection of the CD4+ cell.

48-53. (Canceled)

54. (Currently Amended) The composition of ~~any of claims 1, 2 or 53~~ claim 1 or 2, wherein the PA14 antibody or portion thereof is a humanized antibody or portion thereof.

55. (Currently Amended) The composition of ~~any of claims 1, 2 or 53~~ claim 1 or 2, wherein the PA14 antibody or portion

thereof is a human antibody or portion thereof.

56-57. (Canceled)

58. (Currently Amended) The method of ~~any of claims 46, 47 or 57~~ claim 46 or 47, wherein the PA14 antibody or portion thereof is a humanized antibody or portion thereof.

59. (Currently Amended) The method of ~~any of claims 46, 47 or 57~~ claim 46 or 47, wherein the PA14 antibody or portion thereof is a human antibody or portion thereof.

60. (New) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of claim 1 or 2 effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.

61. (New) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of claim 54 effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.

62. (New) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of claim 55 effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.

63. (New) The method of claim 46 or 47, wherein the CD4+ cell is present in a subject and the contacting is effected by administering the compounds to the subject.

64. (New) The method of claim 58, wherein the CD4+ cell is present in a subject and the contacting is effected by administering the compounds to the subject.

65. (New) The method of claim 59, wherein the CD4+ cell is present in a subject and the contacting is effected by administering the compounds to the subject.

66. (New) The method of claim 60, wherein the CD4+ cell is present in a subject and the contacting is effected by administering the compounds to the subject.